SpringWorks Therapeutics Inc (SWTX) concluded trading on Wednesday at a closing price of $46.21, with 6.07 million shares of worth about $280.36 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 26.78% during that period and on May 21, 2025 the price saw a loss of about -0.22%. Currently the company’s common shares owned by public are about 74.99M shares, out of which, 72.92M shares are available for trading.
Stock saw a price change of -0.02% in past 5 days and over the past one month there was a price change of 14.10%. Year-to-date (YTD), SWTX shares are showing a performance of 27.90% which increased to 3.06% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $28.21 but also hit the highest price of $62.00 during that period. The average intraday trading volume for SpringWorks Therapeutics Inc shares is 4.74 million. The stock is currently trading 0.30% above its 20-day simple moving average (SMA20), while that difference is up 3.81% for SMA50 and it goes to 15.21% higher than SMA200.
SpringWorks Therapeutics Inc (NASDAQ: SWTX) currently have 74.99M outstanding shares and institutions hold larger chunk of about 97.81% of that.
The stock has a current market capitalization of $3.48B and its 3Y-monthly beta is at 0.70. It has posted earnings per share of -$3.41 in the same period. It has Quick Ratio of 4.18 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SWTX, volatility over the week remained 0.37% while standing at 1.25% over the month.
Stock’s fiscal year EPS is expected to rise by 20.99% while it is estimated to increase by 69.98% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on November 20, 2024 offering an Outperform rating for the stock and assigned a target price of $60 to it. Coverage by Guggenheim stated SpringWorks Therapeutics Inc (SWTX) stock as a Buy in their note to investors on February 05, 2024, suggesting a price target of $75 for the stock. On December 01, 2022, BofA Securities Initiated their recommendations, while on January 19, 2021, H.C. Wainwright Reiterated their ratings for the stock with a price target of $101. Stock get a Buy rating from H.C. Wainwright on October 29, 2020.
